Development of adjuvant-combined vaccines for enhanced humoral and cellular immune responses

Current vaccines can prevent many infectious diseases but are ineffective against cancers and diseases such as malaria and HIV. This project will use a novel nanoparticle vaccine delivery platform to regulate the function of dendritic cells (DCs), a key player in immune responses. Antigens and adjuvants that boost the immune response (such as CpG, polyI:C, LPS) and siRNAs will be assembled onto layered double hydroxide (LDH) nanoparticles and their effects on DC-mediated T cell activation will be investigated. This project will help develop more efficient adjuvant combinations to enhance immune responses, enabling the design of new-generation vaccines.